ASP 1893
Alternative Names: ASP-1893Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Antineoplastics
- Mechanism of Action Claudin 6 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Dec 2024 Astellas Pharma terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/unresectable, Second-line therapy or greater) prior to enrolment due to business decision of not initiate this study (IV, Infusion) (NCT06681870)
- 08 Nov 2024 Preclinical trials in Solid tumours in Japan (IV)
- 08 Nov 2024 Astellas Pharma plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/unresectable, Second-line therapy or greater) (IV, Infusion) (NCT06681870)